Cat. No.: HY-P10387

RSM3

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

RSM3 is a METTL3-METTL14 complex inhibitor with a K_d of 3.10 μM for the METTL3-METTL14 complex. RSM3 reduces the m⁶A modification level of SLC31A1 and the global RNA methylation level. RSM3 upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 is applicable to the research of preeclampsia and cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 95.73%
Formule: C₁₃₀H₂₁₈N₅₄O₂₆S₃
Masse moléculaire:3049.66

Stockage:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

RSM3 Chemical Structure

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform Caspase :

In Vitro

RSM3 inhibits the methyltransferase activity of the purified METTL3-METTL14 complex by 45.5%^[1].
RSM3 inhibits the viability of CCRF-CEM leukemia cells with an IC₅₀ of 4.6 μM^[1].
RSM3 inhibits the viability of DU145 prostate cancer cells with an IC₅₀ of 25.8 μM^[1].
RSM3 inhibits the viability of ASPC-1 pancreatic cancer cells with an IC₅₀ of 33.8 μM^[1].
RSM3 inhibits the viability of PC3 prostate cancer cells with an IC₅₀ of 26.5 μM^[1].
RSM3 (15 μM; 24 h) reduces the migratory capacity of PC3 and DU145 prostate cancer cells^[1].
RSM3 (15 μM) induces G1 phase cell cycle arrest and apoptosis in PC3 and DU145 prostate cancer cells^[1].
RSM3 (25 μM; 12 h) reduces the protein levels of METTL3 and METTL14 in PC3 prostate cancer cells^[1].
RSM3 (25 μM; 12 h) inhibits the activity of the ERK/MAPK signaling pathway in PC3 prostate cancer cells by reducing the phosphorylation level of p42/44^[1].
RSM3 (12 h) reduces the global RNA m⁶A modification level in PC3 and DU145 prostate cancer cells^[1].
RSM3 (25 μM; 12 h) induces a specific transcriptomic response in PC3 prostate cancer cells, upregulating programmed cell death, p53 signaling pathway, differentiation and immune pathways, while downregulating cancer proliferation and cell cycle pathways, and enriching gene signatures of apoptosis, p53 and AR pathways^[1].
RSM3 (25 μM; 12 h) upregulates NF-κB, inflammation, apoptosis and luminal differentiation-related genes, and downregulates cell cycle, proliferation and stemness-related genes in PC3 prostate cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[1]

Cell Line:

PC3 and DU145 (prostate cancer) cells
Concentration:

15 μM
Incubation Time:

24 h
Result:

Resulted in approximately a 2-3 fold reduction in cell migration in PC3 and DU145 cells.

Western Blot Analysis^[1]

Cell Line:

PC3 (prostate cancer) cells
Concentration:

25 μM
Incubation Time:

12 h
Result:

Reduced the protein levels of METTL3 and METTL14 in PC3 cells.\n
Reduced phosphorylation levels of p42/44 (ERK1/2).

Real Time qPCR^[1]

Cell Line:

PC3 (prostate cancer) cells
Concentration:

25 μM
Incubation Time:

12 h
Result:

Upregulated NF-kB responsive, inflammatory, apoptosis, and luminal differentiation (AR, PSA, NKX3.1, CK18) genes, and downregulated cell cycle, proliferation, and stemness genes.

In Vivo

RSM3 (50 mg/kg; i.p.; single administration) shows no obvious acute toxicity in C57BL/6 mice^[1].
RSM3 (20 mg/kg; peritumoral injection; once every 2 days; for 14 consecutive days) inhibits the growth of PC3/ASPC-1 xenografts in mice^[1].
RSM3 (50 mg/kg; intraperitoneal injection; daily; 11 days) significantly improves preeclampsia (PE)-related symptoms in rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Immunocompromised mice treated PC3 cells (xenograft model)^[1]
Dosage:

20 mg/kg
Administration:

peri-tumoral injection; every 2 days; 14 days
Result:

Reduced tumor volumes, average tumor mass.
Decreased METTL3 expression and global m6A levels in tumor tissue.
Increased Caspase-3 expression, decreased Ki67 expression in tumor tissue.
Showed no significant changes in body weight.
Detected no histopathological abnormalities in heart, liver, spleen, lung, or kidney tissue.

Animal Model:

Immunocompromised mice treated ASPC-1 cells (xenograft model)^[1]
Dosage:

20 mg/kg
Administration:

peri-tumoral injection; every 2 days; 14 days
Result:

Reduced tumor volume.
Lowered average tumor mass.

Animal Model:

Sprague-Dawley (SD) (female, 7-week-old, 200-220 g, PE model)^[2]
Dosage:

50 mg/kg
Administration:

i.p.; daily; GD 10 to GD 20
Result:

Significantly reduced systolic blood pressure.
Significantly reduced 24-hour urine protein concentration.
Significantly reduced urine albumin to creatinine ratio.
Significantly lowered placental METTL3 protein expression.
Significantly increased placental SLC31A1 protein expression.
Significantly reduced m6A modification level of SLC31A1 in placental tissue.

Chemical Information

Appearance Solid
Masse moléculaire 3049.66
Formule C₁₃₀H₂₁₈N₅₄O₂₆S₃
Color White to off-white
Sequence

Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys-Met-Glu-Leu-Gly-Arg-Glu-Cys-Leu-Asn-Leu-Trp-NH2 (Stapled between two Cys via bhp)
Sequence Shortening

RRRRRRRRRCMELGRECLNLW-NH2 (Stapled between two Cys via bhp)
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (1)

All

Sort by:

Journal Impact Factor

Placenta

METTL3 suppressing SLC31A1 m6A modification regulates trophoblast migration and invasion. [Abstract]

2025 May 2:164:21-30. PMID: 40088504

Solvant et solubilité

In Vitro:

H₂O : ≥ 25 mg/mL (8.20 mM)

DMSO : 25 mg/mL (8.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.3279 mL

1.6395 mL

3.2791 mL

5 mM

0.0656 mL

0.3279 mL

0.6558 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (290 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Li Z, et al. A Stapled Peptide Inhibitor Targeting the Binding Interface of N6-Adenosine-Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy. Angew Chem Int Ed Engl. 2024;63(24):e202402611. [Content Brief]

[2]. Wang S, et al. METTL3 suppressing SLC31A1 m⁶A modification regulates trophoblast migration and invasion. Placenta. 2025;164:21-30. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	0.3279 mL	1.6395 mL	3.2791 mL	8.1976 mL
H₂O / DMSO	5 mM	0.0656 mL	0.3279 mL	0.6558 mL	1.6395 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

RSM3

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Peptide Library

Pain-Related Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

Peptide Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) RSM3

Voir tous les produits spécifiques à Isoform NF-κB

Voir tous les produits spécifiques à Isoform Caspase